Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT2 | O75908 | 1/20 | 0.57 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.57 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 5/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.34 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 6/20 | 0.33 |
| ▸ | NAAA | Q02083 | 2/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5900901 | 1.00 | SOAT2 (0.57) | SOAT2ACAT1SOAT1LMNAALOX12 | |
| SCHEMBL8416085 | 0.87 | SOAT2 (0.44) | SOAT2ACAT1SOAT1LMNAALOX12 | |
| SCHEMBL8417196 | 0.84 | SOAT2 (0.42) | SOAT2ACAT1SOAT1LMNAMAPT | |
| SCHEMBL8417517 | 0.83 | SOAT1 (0.47) | SOAT2ACAT1SOAT1LMNAMAPT | |
| SCHEMBL8043457 | 0.81 | SOAT1 (0.47) | SOAT2ACAT1SOAT1LMNAMAPT | |
| SCHEMBL8041447 | 0.81 | SOAT2 (0.47) | SOAT2ACAT1SOAT1LMNAMAPT | |
| SCHEMBL8049433 | 0.80 | SOAT2 (0.46) | SOAT2ACAT1SOAT1LMNAMAPT | |
| SCHEMBL8042243 | 0.80 | SOAT2 (0.46) | SOAT2ACAT1SOAT1LMNAMAPT | |
| SCHEMBL8049340 | 0.79 | SOAT1 (0.45) | SOAT2ACAT1SOAT1LMNAMAPT | |
| SCHEMBL13249165 | 0.75 | SOAT2 (0.73) | SOAT2ACAT1SOAT1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192245-A1 | Medicinal composition for treating arteriosclerosis | SANKYO COMPANY, LIMITED (JP) | 2005-09-01 | — | — | US | claimed |
| EP-1555032-A1 | MEDICINAL COMPOSITION FOR TREATING ARTERIOSCLEROSIS | Sankyo Company, Limited (JP) | 2005-07-20 | — | — | EP | claimed |
| US-10925885-B2 | Thyromimetics for the treatment of fatty liver diseases | METABASIS THERAPEUTICS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10420781-B2 | Thyroid hormone receptor agonist and use thereof | METABASIS THERAPEUTICS INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20190083515-A1 | THYROMIMETICS FOR THE TREATMENT OF FATTY LIVER DISEASES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-03-21 | — | — | US | disclosed |
| US-20180344752-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | METABASIS THERAPEUTICS INC. | 2018-12-06 | — | — | US | disclosed |
| US-10130643-B2 | Thyromimetics for the treatment of fatty liver diseases | METABASIS THERAPEUTICS, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20170319604-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | METABASIS THERAPEUTICS, INC. | 2017-11-09 | — | — | US | disclosed |
| WO-2017184811-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | METABASIS THERAPEUTICS, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| US-20170112864-A1 | Thyromimetics for the Treatment of Fatty Liver Diseases | METABASIS THERAPEUTICS, INC. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20120046364-A1 | Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use | METABASIS THERAPEUTICS, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2006128058-A2 | THYROMIMETICS FOR THE TREATMENT OF FATTY LIVER DISEASES | METABASIS THERAPEUTICS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006128056-A2 | NOVEL PHOSPHINIC ACID-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060046980-A1 | Novel phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. | 2006-03-02 | — | — | US | disclosed |
| US-20050192245-A1 | Medicinal composition for treating arteriosclerosis | SANKYO COMPANY, LIMITED (JP) | 2005-09-01 | — | — | US | disclosed |
| EP-1555032-A1 | MEDICINAL COMPOSITION FOR TREATING ARTERIOSCLEROSIS | Sankyo Company, Limited (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-20050119314-A1 | Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent | SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| EP-1493448-A1 | MEDICINAL COMPOSITION COMPRISING ACAT INHIBITOR AND INSULINE RESISTANCE IMPROVING AGENT | Sankyo Company, Limited (JP) | 2005-01-05 | — | — | EP | disclosed |
| US-20040198788-A1 | Medicinal compositions containing angiotensin II receptor antagonist | SANKYO COMPANY, LIMITED (JP) | 2004-10-07 | — | — | US | disclosed |
| EP-1421953-A1 | MEDICINAL COMPOSITIONS CONTAINING ANGIOTENSIN II RECEPTOR ANTAGONIST | Sankyo Company, Limited (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112864-A1 | Thyromimetics for the Treatment of Fatty Liver Diseases | TSHR, THRA, FABP1 | SOAT2 426/4885ACAT1 210/4885SOAT1 463/4885 |
| US-10420781-B2 | Thyroid hormone receptor agonist and use thereof | THRB, THRA, TSHR | SOAT2 533/4885ACAT1 781/4885SOAT1 384/4885 |
| US-10925885-B2 | Thyromimetics for the treatment of fatty liver diseases | TSHR, THRA, FABP1 | SOAT2 426/4885ACAT1 210/4885SOAT1 463/4885 |
| US-20120046364-A1 | Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use | THRB, TSHR, THRA | SOAT2 591/4885ACAT1 660/4885SOAT1 322/4885 |
| US-20040198788-A1 | Medicinal compositions containing angiotensin II receptor antagonist | AGTR2, AGTR1, AGT | SOAT2 357/4885ACAT1 14/4885SOAT1 419/4885 |
| US-20190083515-A1 | THYROMIMETICS FOR THE TREATMENT OF FATTY LIVER DISEASES | TSHR, THRA, FABP1 | SOAT2 432/4885ACAT1 220/4885SOAT1 462/4885 |
| US-20060046980-A1 | Novel phosphorus-containing thyromimetics | PYGL, THRA, THOP1 | SOAT2 1470/4885ACAT1 886/4885SOAT1 942/4885 |
| US-20180344752-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | THRB, THRA, TSHR | SOAT2 533/4885ACAT1 781/4885SOAT1 384/4885 |
| US-20170319604-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | THRB, THRA, TSHR | SOAT2 533/4885ACAT1 781/4885SOAT1 384/4885 |
| US-10130643-B2 | Thyromimetics for the treatment of fatty liver diseases | TSHR, THRA, FABP1 | SOAT2 426/4885ACAT1 210/4885SOAT1 463/4885 |
| US-20050119314-A1 | Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent | ACAT2, ACAT1, ACACA | SOAT2 71/4885ACAT1 2/4885SOAT1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.